Drugs which are not patentable

Slides:



Advertisements
Similar presentations
H I R S C H & P A R T N E R S A v o c a t S o l i c i t o r R e c h t s a n w a l t CHEMICAL INVENTIONS IN FRANCE Recent decisions and case law Dr Denis.
Advertisements

REVOCATION SCENARIO IN INDIA By, Shailee Gupta Women Scientist
The Intellectual Property Rights Regime in India & US: The Evolving Landscape February 15, 2014, The Hyatt Regency Hotel, New Delhi D. CALAB GABRIEL.
Getting Your Startup to Work for You How Innovators Can Use US Patent Law to Protect Their Startups Shelly Rosenfeld Lewis Brisbois Bisgaard & Smith LLP.
Oppositions made simple How to start: Leena Menghaney, MSF Access Campaign.
CAMBRIDGE UNIVERSITY UK Robinson College – Faculty of Law 23rd Annual Fordham Conference Intellectual Property Law and Policy 8 – 9 April 2015 Patent Session.
BLAW 2010 Patent Project Part 1I. Why do we have patent laws?
INTRODUCTION TO PATENT RIGHTS The Business of Intellectual Property
10 April Probiotics are Live microorganisms which when administered in adequate amounts confer a health benefit on the host. Probiotics have been.
Antibody Patents in India Pravin Anand 14 th October 2011 Anand and Anand.
The Story of IP Coming to India…. Dr. Srividhya Ragavan Professor of Law University of Oklahoma College of Law
Prof. Frederick M. Abbott Harvard Human Rights Journal Symposium April 11, 2013 Cambridge, USA.
Consultant F. Hoffmann La Roche
Biopiracy Biopiracy is defined as, “the illegal appropriation of life – micro-organisms, plants and animals (including humans) and the traditional knowledge.
Intellectual Property Patent Primer Michael Pratt Executive Director, Business Development November 1, 2011.
Patents 101 April 1, 2002 And now, for something new, useful and not obvious.
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
A New Pathway for Follow-on Biologics Presented by: Steve Nash May 7, 2010.
Ms. Arpita Sawhney Patent Law In India: Questions Outstanding.
How to operationalize the disclosure requirement at the national level in a manner supportive to the TRIPS Agreement and the CBD? Dr. N.S. Gopalakrishnan,
INDIAN PATENT SYSTEM Recent Advances IPR ADVANTAGE : Dr. W.M. DHUMANE
Intellectual Property
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA AN OVERVIEW OF PATENT PROTECTION IN ZAMBIA.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
TRIPS Flexibilities Preventive Measures Johanna von Braun, PhD University of Cape Town, South Africa Kiev, 21/22 nd June, 2010.
SAREE AONGSOMWANG Foundation for Consumers, Thailand.
11 Indirect Infringement of Patent for Combination of Drugs Kaoru Kuroda, Attorney at Law Abe, Ikubo & Katayama ABE, IKUBO & KATAYAMA.
UNNI NALSAR The Fascinating World of Patents Seminar on Industrial Property, 25 th January 2007 At Hotel International, Kochi Organised by EU-India TIDP.
1 American University Thursday 21 February 2013 Patents and the right to health Duncan Matthews Centre for Commercial Law Studies Queen Mary, University.
Data protection and extension of patent rights TRIPS requirements & TRIPS-plus provisions Carlos Correa.
PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.
Deadly decisions for People living with HIV Trans Pacific FTA.
EXPERIMENTAL DATA STANDARD REQUIRED FOR PATENTING BIOLOGICAL PHARMA MATERIAL IN INDIA © SNA-2011 Hari Subramaniam Subramaniam, Nataraj & Associates New.
WELCOME TO ALL DELEGATES Assistant Controller of Patents and Designs Govt. of India WELCOME TO ALL DELEGATES By R.Bhattacharya Assistant Controller of.
APAA 54 th Council Meeting 2007 Alelaide, Australia Emerging Intellectual Property Rights Committee Emerging Intellectual Property Rights Committee Decision.
PATENTSHIP. What is a Patent?  Patent  is an exclusive and monopoly right  to use the patented invention  for a limited area and time (20 Years) 
“Inventing the Future” – The Role of Utility Models and Patents in Leveraging Technical Innovation in the Market Place Kingston, Jamaica Jun 4 - 6, 2012.
Professor Peng  Patent Act (2008) ◦ Promulgated in 1984 ◦ Amended in 1992, 2000, and 2008.
© Dr. iur. Martin Schneider Ahmedabad, India - 09/10 February Original vs. Generic Products - Who is Right? Latest developments in European IP Law.
Intellectual Property, Patents & Technology Transfer Sagar Manoli Shashidhar, Philippe Abdel-Sayed Responsible Conduct in Biomedical Research EPFL,
3rd National Conference on medicines policy, Bratislava December 2006 Medicines Policy and equity in health How can generic drug producers contribute?
At Pharmexcil, Chennai 24 th August, 2012 by Dr. Gopakumar G. Nair Advisor to Pharmexcil, India Gopakumar Nair Associates Url:
EXCLUSIVE MARKETING RIGHTS & MAIL-BOX APPLICATIONS BY Manish Kumar Prusty T. Harish.
Post-Bilski Patent Prosecution IP Osgoode March 13, 2009 Bob Nakano McCarthy Tétrault LLP.
Patents and Medicines: How the system has discouraged innovation and reduced patient access to benefits of knowledge GREG PERRY Director General, EGA World.
Introduction to Patents Anatomy of a Patent & Procedures for Getting a Patent Margaret Hartnett Commercialisation & IP Manager University.
(c) 2002 Sandeep K. Rathod Patents: An Introduction A Presentation at Zydus Research Centre Oct. 19, 2002 by Sandeep K. Rathod B. Com, L.L.B. Sr. Exe.
Getting the best treatment to the most people possible Enabling policies: threats & opportunities MSF Access Campaign.
Safe Harbor or Not: Application of 271(e)(1) to Pioneering Drug Discovery Activities Susan Steele October 21, 2003.
Intellectual Property Rights and Pharmaceuticals (Case study- Novartis’s claim in India) Background note prepared for PHM Vic Internet Workshop.
Access to Medicines in Light of Patent Law Regime in India A LEGACY OF LEGISLATION OR LEASE OF THE JUDICIARY?
Opportunities and Challenges for Pharma SMEs in the current Patent regime Deepak Padia Managing Director – Octavius Pharma Pvt. Ltd.
INTELLECTUAL PROPERTY RIGHTS: INNOVATION, ECONOMICS AND ACCESS OF PHARMACEUTICALS BY SANJAY JAIN VP, QUALITY MANAGEMENT AMNEAL PHARMACEUTICALS.
Biotechnology Chemical Pharmaceutical Customer Partnership
LAW OF COMPUTER TECHNOLOGY FALL 2015 © 2015 MICHAEL I. SHAMOS Patents Michael I. Shamos, Ph.D., J.D. Institute for Software Research School of Computer.
Intellectual Property Basics: What Rules Apply to Faculty, Staff, and Student Work Product? Dave Broome Vice Chancellor and General Counsel October 15,
Access to medicines Elizabeth Holzer, Legal Policy Advisor A global and local - legal and health systems issues.
India’s Patent Path. Srividhya Ragavan Associate Professor of Law University of Oklahoma College of Law.
Srividhya Ragavan Professor of Law University of Oklahoma College of Law Crossing Borders from Oklahoma: Beyond Texas...
Introduction: Intellectual Property Rights and its impact on access to medicines Anand Grover United Nations Special Rapporteur on Health East Africa Consultation,
Standards of Patentability and Opposition Procedures: India Patent Act & Novartis v. India Professor Brook K. Baker Health GAP Northeastern University.
1 CHALLENGES IN REGULATION OF TRADITIONAL AND ALTERNATIVE MEDICINES 24 th March, 2010 MOHSW Conference Room Registration of Herbal Drugs.
Class 24: Finish Remedies, then Subject Matter Patent Law Spring 2007 Professor Petherbridge.
Basse Asplund, M Sc, Ph D Patent Attorney and Partner Stockholm, Uppsala, Göteborg och Lund.
© 2015 Waller Lansden Dortch & Davis, LLP. All Rights Reserved. Ready to Patent? Value and Risk Considerations Nicolo Davidson.
The Challenge of Biotech Patent Eligibility in the United States:
Patent law update.
Biotechnology Chemical Pharmaceutical Customer Partnership
Patents, Cannabis, and the Current U.S. Climate
Presentation transcript:

Drugs which are not patentable Dr. M. Krishnaji Rao drkrishnajirao@gmail.com

Introduced to … IPR Prior art search Patentable inventions Patents filing Patent prosecution

Inventions that are patentable Categories of eligible inventions New compounds, new compositions(new formulations) A process for production of new compounds, new materials, new compositions Improvements of an existing process for the production of known compounds, known materials, known composition Synergistic compositions Medical device/improved medical device New machine/device Improved machine/device

Are all new compounds patentable?

New herbal drug Case study Not known to prior art Showing new therapeutic use Not known to person skilled in the art Not known to our traditional medicine or our Indian Aurveda Patent filed

Why new herbal drug patent rejected? Chapter II of Indian patents act, 1970 The patents (Amendment) Rules, 2006 Section 3(j) … plants and animals in whole or any part thereof is not patentable

Case study on drug substance Known drug substance converted to… salts esters ethers polymorphs metabolites pure form particle size isomers mixtures of isomers complexes combinations and derivatives of known substance

why not patentable? Chapter II of Indian patents act, 1970 The patents (Amendment) Rules, 2006 Section 3(d) “the mere discovery of a new form of known substance which does not result in the enhancement of the known efficacy of that substance or the mere discovery of any new property or new use for a known substance or mere use of a known process, machine or apparatus unless such known process results in a new product or employs at least one reactant”

Section 3(d)… What is an objective of section 3(d)? To prevent ever-greening of patents What happens if section 3(d) removed from our act? Would result in “ever-greening” of patents and delays in the entry of generics, thereby affecting public health.

Section 3(d)… What are patentable drugs as per section 3(d)? “ Derivatives with added efficacy patentable” Section 3(d) encourages sequential development of existing products or technologies that help bring in improved products to the market

Analysis of section 3(d) Two case studies: Glivec, a product of 2. Erlotinib, a product of

The Novartis case Novartis claimed the polymorph of crystalline imatinib mesylate (brand name Glivec) in a patent application Patent grant opposed by several Indian companies on several grounds

The Novartis case Whether Novartis’ beta crystalline form is patentable or not under section 3(d)? “enhancement of known efficacy” “efficacy” would mean “therapeutic efficacy”

The Roche case Roche vs Cipla Roche sued Cipla for patent infringement in 2008 and sought an interlocutory injunction. Cipla counter claimed that the patent is invalid and should be revoked. Cipla also argued the price difference between the two drugs and the public interest in making life-saving drugs available at an affordable price.

The Roche case The Delhi high court passed an order rejecting the prayer of Roche for an injunction No inventive step

The Roche case Further analysis of section 3(d)… Let us consider two possibilities: Gifatinib Erlotinib Erlotinib is not a derivative of Gefatinib: Section 3(d) does not apply Erlotinib is a derivative of Gefatinib: Section 3(d) applies Relevance of Orphan Drug Act in the context of section 3(d)

Case study… New drug substance produced by bio-catalytic process, wherein catalysis performed by using microorganism, which was isolated from soil Can we get a patent for microorganism? Section 3(c) …discovery of any living or non-living substance is not patentable

Case study… “A drug substance, which is a mixture of two drugs having two therapeutic activities which improved patient compliance by taking single dose instead of two drugs individually” Can we get a patent for the new drug mixture? No Section 3(e) A substance obtained by a mere admixture resulting only in the aggregation of the properties of the components thereof

Case study “A drug substance which has wound healing property but known to traditional knowledge” Not patentable Section 3(p) Traditional Knowledge or an aggregation or duplication of known properties of traditionally known component or components

In conclusion The inventions pertaining to drug substances, which fall under section 3 of Indian patent act are not patentable

Be honest to become rich otherwise your attorney becomes rich Krishnaji Rao